ScoreWhy is Theravance Biopharma, Inc. ?
1
With a growth in Net Sales of 18.51%, the company declared Outstanding results in Sep 25
- OPERATING CASH FLOW(Y) Highest at USD 243.7 MM
- NET SALES(HY) At USD 46.19 MM has Grown at 48.39%
- ROCE(HY) Highest at 14.03%
2
With ROE of 12.61%, it has a very attractive valuation with a 3.03 Price to Book Value
- Over the past year, while the stock has generated a return of 55.59%, its profits have risen by 165.4% ; the PEG ratio of the company is 0.2
3
High Institutional Holdings at 100%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
4
Market Beating Performance
- The stock has generated a return of 55.59% in the last 1 year, much higher than market (S&P 500) returns of 14.90%
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Theravance Biopharma, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Theravance Biopharma, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Theravance Biopharma, Inc.
60.15%
1.19
54.31%
S&P 500
14.9%
0.77
19.29%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-0.56%
EBIT Growth (5y)
13.45%
EBIT to Interest (avg)
-10.30
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.54
Sales to Capital Employed (avg)
0.29
Tax Ratio
20.64%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
24
Industry P/E
Price to Book Value
3.03
EV to EBIT
-11.02
EV to EBITDA
-13.07
EV to Capital Employed
-4.50
EV to Sales
4.82
PEG Ratio
0.15
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
12.61%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend26What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD 243.7 MM
NET SALES(HY)
At USD 46.19 MM has Grown at 48.39%
ROCE(HY)
Highest at 14.03%
NET PROFIT(Q)
At USD 3.62 MM has Grown at 132.46%
RAW MATERIAL COST(Y)
Fallen by -2.45% (YoY
DEBT-EQUITY RATIO
(HY)
Lowest at -122.52 %
DEBTORS TURNOVER RATIO(HY)
Highest at 4.58 times
PRE-TAX PROFIT(Q)
At USD -2.89 MM has Grown at 65.97%
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Here's what is working for Theravance Biopharma, Inc.
Operating Cash Flow
Highest at USD 243.7 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Profit
At USD 3.62 MM has Grown at 132.46%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very positive
Net Profit (USD MM)
Net Sales
At USD 46.19 MM has Grown at 48.39%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Pre-Tax Profit
At USD -2.89 MM has Grown at 65.97%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Debt-Equity Ratio
Lowest at -122.52 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Debtors Turnover Ratio
Highest at 4.58 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -2.45% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
